Upadacitinib is a selective and reversible JAK1 inhibitor approved for treating various autoimmune diseases, such as RA, atopic dermatitis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.[3,4,5,6,7,8] Here, we present two patients with recalcitrant uveitis with successful response to upadacitinib, a case of birdshot chorioretinopathy (BCR), and a patient with chronic anterior and intermediate uveitis associated with Crohn's disease who initiated this treatment by their rheumatologists. The gene discussed is JAK1; the disease is Crohn disease.